The effect of supplemental whey protein timing on postprandial glycaemia in centrally obese males by Allerton DM et al.
1 
 
The effect of supplemental whey protein timing on postprandial glycaemia in 
centrally-obese males 
 
 
Dean M. Allerton1, Penny L. S. Rumbold2, Daniel J. West3, Emma J. Stevenson3 
 
1 School of Biomedical Sciences, Newcastle University, Newcastle upon Tyne, UK. 
2 Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, UK. 
3 Human Nutrition Research Centre, Institute of Cellular Medicine, Newcastle University, Newcastle 
upon Tyne, UK. 
 
 
 
Running title: Whey protein timing and glycaemia 
 
 
 
Corresponding author:  
Professor Emma Stevenson 
Institute of Cellular Medicine, 
Newcastle University,  
Newcastle upon Tyne,  
NE2 4HH,  
UK. 
 
Tel: 0191 208 7865 
Email: emma.stevenson@newcastle.ac.uk  
 
 
 
 
 
Key words:  Whey protein  Postprandial  Glucose  Insulin  Appetite 
2 
 
ABSTRACT 1 
 2 
Consuming whey protein prior to a meal may reduce postprandial glucose excursions, however 3 
optimising timing of supplementation is important to improve its clinical utility. Thirteen centrally-4 
obese, insulin resistant males (waist circumference: 121 (SEM 3) cm; HOMA-IR: 6.4 (SEM 1.2)) 5 
completed four experimental conditions in a single-blind, crossover design. Participants consumed 6 
mixed-macronutrient breakfast and lunch meals on all occasions, with 20 g whey protein consumed 7 
15 min prior to (PRE), alongside (DUR) or 15 min post-breakfast (POST), or omitted (CON). 8 
Capillary glucose and plasma concentrations of insulin, triglycerides and NEFA, in addition to 9 
subjective appetite ratings, were collected for 180 min after each meal. PRE and DUR reduced post-10 
breakfast glucose peak by 17.0 (SEM 1.9)% (P < 0.001) and 9.2 (SEM 2.9)% (P = 0.046) respectively, 11 
compared with CON. Post-breakfast glucose AUC was lower following PRE compared with POST 12 
and CON (PRE: 982 (SEM 30) vs POST: 1031 (SEM 36) and CON: 1065 (SEM 37) mmol/l x 180 min; P 13 
≤ 0.042), but similar to DUR (1013 (SEM 32) mmol/l x 180 min; P = 0.77). Insulin was lower during 14 
PRE, when compared with POST and DUR (both P ≤ 0.042), but similar to CON. There were no 15 
between-condition differences in measures of postprandial lipaemia or appetite, and no effect of 16 
condition post-lunch. Consumption of whey protein as a preload or alongside a mixed-macronutrient 17 
breakfast reduces postprandial glucose excursions in centrally-obese, insulin resistant males. Whey 18 
consumed as a preload has superior glycaemic lowering effects. Supplementation at breakfast does 19 
not alter glycaemic responses to subsequent meals.  20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
 28 
 29 
 30 
 31 
 32 
 33 
 34 
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INTRODUCTION 35 
 36 
Central obesity is associated with insulin resistance and an increased risk of developing type 2 37 
diabetes and cardiovascular disease 1,2. In those without diagnosed type 2 diabetes, postprandial 38 
glucose excursions are a stronger predictor of HbA1c than fasting glucose, and also increase the risk 39 
of cardiovascular disease 3-5. Postprandial hyperglycaemia, no matter how brief, drives inflammation, 40 
oxidative stress and vascular dysfunction 6-9. Thus, individuals who are centrally-obese and insulin 41 
resistant may benefit from strategies that ameliorate postprandial hyperglycaemic excursions 10.  42 
 43 
Recent non-pharmaceutical interventional studies have sought to reduce postprandial hyperglycaemia 44 
through whey protein supplementation (for review 11). Whey protein contains an abundant source of 45 
amino acids and bioactive peptides that are rapidly digested. These act as potent insulin secretagogues 46 
and can reduce gastric emptying, hepatic glucose production, and can increase satiety 12-16. Despite 47 
many trials in normal-weight populations or individuals with type 2 diabetes, few studies have been 48 
conducted using centrally-obese participants without metabolic disease. This is surprising given that 49 
such individuals are likely to be exposed to elevated postprandial glycaemic excursions 17 and their 50 
associated adverse metabolic effects 18. 51 
 52 
There are practical limitations associated with implementing pre-meal whey protein as a strategy to 53 
reduce postprandial hyperglycaemia. Firstly, studies have investigated the glycaemic response to 54 
single test meals of primarily high glycaemic index carbohydrate content 19,20, without investigating 55 
if the whey supplementation effects carry forward to subsequent meals. Secondly, dosages of whey 56 
protein administered are generally unrealistically large (45-55 g; ~200 kcal) 19,21. Furthermore, whey 57 
protein has shown most benefit when supplemented as a preload around 30 min before the main meal 58 
19,22, thus restricting its ecological validity when applied in free-living conditions, as this does not 59 
reflect conventional eating habits 23. From a clinical viewpoint it is important to establish whether the 60 
beneficial effect of whey supplementation is retained at smaller doses, if the whey bolus is beneficial 61 
when consumed alongside or after the meal, and if the therapeutic effects influence glycaemia at 62 
subsequent meal times in centrally-obese insulin resistant individuals.  63 
 64 
The purpose of this study was to investigate the effect of a realistic whey protein dose on postprandial 65 
metabolic and appetite responses in centrally-obese insulin resistant individuals, using timings and 66 
test meals that reflect habitual eating behaviours. We hypothesise that whey protein consumption will 67 
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reduce the postprandial glucose response and positively affect subjective appetite, with more 68 
favourable effects resulting from earlier supplementation. 69 
 70 
 71 
METHODS 72 
 73 
Participants 74 
 75 
Centrally-obese male participants, free from metabolic disease, were recruited from the local 76 
community. Participants who met the inclusion criteria for gender (male), age (18-55 years), waist 77 
circumference (>102 cm) and physical activity level (low) were included in the study (n = 13; see 78 
Table 1 for participant characteristics). The waist circumference criterion value was based on the 79 
WHO threshold associated with the greatest risk of metabolic complications in males 24. This was 80 
measured at the mid-point between the lower costal border and the illiocristale, according to 81 
International Society for the Advancement of Kinanthropometry (ISAK) guidelines 25. Physical 82 
activity level was assessed using the categorical scoring method following completion of the 83 
International Physical Activity Questionnaire 26.  84 
 85 
Ethical approval 86 
 87 
This study was conducted according to the guidelines laid down in the Declaration of Helsinki and 88 
all procedures were approved by the Faculty of Health and Life Sciences Research Ethics Committee 89 
(reference: HLSDA020415). All participants provided prior written informed consent. This study was 90 
registered at clinicaltrials.gov (NCT02658110). 91 
 92 
Study design 93 
 94 
Participants completed four experimental conditions in a randomised order, as part of a single-blind, 95 
crossover design. Each condition was separated by at least 3 days. On all visits participants consumed 96 
a standardised mixed-macronutrient breakfast meal, followed 180 min later by consumption of a 97 
standard lunch meal. The timing of additional protein supplementation varied by condition, with 98 
participants consuming 20 g whey protein as a preload 15 min prior to breakfast (PRE), during the 99 
breakfast meal (DUR), or 15 min post-breakfast consumption (POST). A control condition was also 100 
completed without additional protein supplementation (CON).  101 
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 102 
Pre-trial standardisation 103 
 104 
Prior to each experimental visit participants were provided with verbal and written instructions 105 
regarding diet and physical activity control measures. For 24 hours prior to arrival participants were 106 
instructed to avoid caffeine and alcohol consumption as well as strenuous physical activity. A mixed-107 
macronutrient meal was provided before each visit (3501 kJ; 37/19/44% energy from 108 
carbohydrate/protein/fat), and participants were instructed to consume this as their evening meal 12 109 
hours prior to their arrival time, in order to standardise macronutrient and energy intake.  110 
 111 
Experimental protocol 112 
 113 
The experimental protocol is presented in Figure 1. Participants arrived at the laboratory at the same 114 
time (~08.00 hours) on each occasion following an overnight fast. After insertion of a cannula in an 115 
antecubital vein, baseline venous and capillary blood samples were collected and subjective appetite 116 
was assessed using visual analogue scales. In the PRE condition, participants consumed a 20 g whey 117 
protein beverage, with flavoured water (placebo) provided in all other conditions. After a further 15 118 
min, breakfast was consumed in all conditions, accompanied by either a whey protein (DUR) or 119 
placebo test drink (POST and CON). At 15 min post-breakfast consumption, a further test drink was 120 
provided, with whey protein administered in the POST condition and flavoured water during all other 121 
conditions. The remainder of the protocol was identical under all experimental conditions, with blood 122 
samples and appetite ratings collected at regular intervals (Figure 1). Participants rested in a seated 123 
position for 180 min following breakfast consumption, after which a standardised lunch meal was 124 
consumed. Following a further period of seated rest (180 min), the cannula was removed and 125 
participants were able to leave the laboratory.  126 
 127 
Test meals 128 
 129 
At each test drink time point (15 min before, during or 15 min after breakfast) either a whey protein 130 
or placebo drink was consumed which was condition-dependent. The protein drink contained 23g 131 
whey protein isolate powder (Lacprodan SP-9225 Instant; Arla Food Ingredients Group, Viby, 132 
Denmark) mixed with 150 ml water and 0.5 ml energy-free strawberry flavouring (FlavDrops, 133 
Myprotein, UK), providing 20 g protein (87% protein content) and 343 kJ (82 kcal) energy. The 134 
placebo drink was matched for volume and taste using similarly flavoured water. All drinks were 135 
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provided in opaque bottles and no reference was made to which condition was being conducted. An 136 
additional 200 ml drinking water was administered after each test beverage to eliminate any after 137 
taste.  138 
 139 
A standardised breakfast of rolled oats (54.0 g) with semi-skimmed milk (260 ml) and honey (42.5 140 
g) was provided under all conditions as a semi-liquid porridge mixture. This provided 1958 kJ (468 141 
kcal) of energy (70% carbohydrate, 17% fat, 13% protein). Participants were encouraged to consume 142 
this meal within 10 min. Porridge was selected to represent a habitually consumed breakfast food 143 
amongst the UK population 27 which provides a mixed macronutrient composition.  144 
 145 
A standardised mixed-macronutrient lunch meal was provided in all conditions, as described 146 
previously 28. A 125 g portion of dried fusilli pasta was cooked and combined with 170 g of a tomato-147 
based sauce (Dolmio, Mars, USA), grated cheddar cheese (40 g) and olive oil (15 g). The resulting 148 
homogenous meal provided 3448 kJ (824 kcal) of energy (50% carbohydrate, 36% fat, 14% protein). 149 
Participants were again instructed to finish the entire meal within 10 min. Water (500 ml) was also 150 
served alongside the lunch meal, and was withheld in the post-lunch period.  151 
 152 
Blood sampling and analysis 153 
 154 
On arrival, a cannula (Vasofix 22G, B.Braun Melsungen AG, Germany) was inserted into a vein in 155 
the antecubital fossa while participants remained in a semi-supine position. At each sample point, 156 
10 ml of whole venous blood was drawn into a syringe and transferred into an EDTA coated tube 157 
(Vacutainer, Becton Dickinson, USA) followed by centrifugation at 1734 g and 4˚C for 10 min 158 
(Allegra X-22R, Beckman Coulter, USA). Plasma was aliquoted into separate microtubes and stored 159 
at -80˚C for subsequent analysis. Sterile stylets (22G, B.Braun Melsungen AG, Germany) were 160 
inserted to keep the cannula patent between blood samples. To control for any postural changes in 161 
plasma volume participants were instructed to remain in a seated position throughout the protocol 162 
where possible. 163 
 164 
Capillary blood samples (20 µl) were collected immediately following each venous blood draw using 165 
the finger-prick technique and processed for glucose (Biosen C_line analyser, EKF Diagnostics, UK). 166 
Additional samples were collected at 5 and 10 min post-meal in order to increase the resolution of 167 
the blood glucose curve during the period where rapid changes may occur. Venous samples were 168 
processed and analysed for concentrations of plasma insulin, NEFA and triglyceride. Insulin 169 
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concentrations were determined using a commercially available ELISA (IBL International, Hamburg, 170 
Germany), with intra and inter-assay variation (CV) of 5.9% and 8.9% respectively. NEFA and 171 
triglyceride concentrations were determined by enzymatic colorimetric assays using an automated 172 
analyser (RX Daytona, Randox Laboratories, UK) according to manufacturer instructions.  173 
 174 
Subjective appetite 175 
 176 
Subjective ratings of appetite were captured at baseline and at regular intervals throughout (Figure 177 
1). The reproducibility of within-subject responses and the sensitivity to experimental manipulations 178 
for this technique have previously been established  29. Paper-based 100 mm scales were used to 179 
record perceptions of hunger, fullness, satisfaction and prospective food consumption (PFC).  180 
 181 
Statistical analysis 182 
 183 
A sample size calculation was performed using a reduction in postprandial glycaemia (AUC) as the 184 
primary outcome. Based on the observed 16% reduction in glucose AUC following consumption of 185 
whey protein with a mixed-macronutrient breakfast in an overweight/obese population 30, it was 186 
calculated that a sample size of 11 would provide statistical power above 80%, with a two-sided alpha 187 
level of 0.05. To account for a 20% dropout, a minimum of 13 participants was targeted.  188 
 189 
Serial measures of blood analytes and subjective appetite responses were used to calculate AUC using 190 
the trapezoidal method. The resultant total AUC includes all area below the response curve in order 191 
to take account of situations where concentrations fell below baseline 31. Insulin sensitivity was 192 
assessed using the Matsuda Insulin Sensitivity Index (ISI), calculated using fasting and postprandial 193 
concentrations of plasma glucose and plasma insulin 32. A combined appetite score (CAS), was used 194 
to combine the four aspects of subjective appetite assessment, as described previously 33.  195 
 196 
Statistical analysis was conducted using SPSS (version 21, IBM, USA). Blood and plasma analyte 197 
concentrations and subjective appetite responses were tested for differences between conditions over 198 
time using two-way (condition x time) repeated measures ANOVA. Area under the curve was 199 
analysed using one-way ANOVA. Post hoc analysis was performed upon identification of significant 200 
main effects and the Bonferroni correction was used to correct the level of alpha for multiple 201 
comparisons. The level of statistical significance was set at p < 0.05 and data are presented as 202 
mean values with their standard errors. 203 
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 204 
 205 
RESULTS 206 
 207 
Post-breakfast responses 208 
 209 
Fasting values did not differ between conditions for all physiological and appetite variables assessed 210 
(P > 0.05). Blood glucose responses displayed a significant condition x time interaction effect 211 
(P < 0.001) in addition to main effects of condition (P < 0.001) and time (P < 0.001). Glucose peaked 212 
at 30 min post-breakfast under all conditions (Figure 2a), with the magnitude of the peak significantly 213 
reduced when whey protein was consumed as a preload or alongside breakfast compared with whey 214 
after the meal or no supplementation (PRE: 7.2 (SEM 0.3), DUR: 7.8 (SEM 0.3) vs POST: 8.6 (SEM 0.3), 215 
CON: 8.6 (SEM 0.2) mmol/l; all P ≤ 0.046). A tendency for peak glucose to be reduced in PRE 216 
compared to DUR was also observed, however this was not statistically significant (P = 0.076). 217 
Compared to CON, glucose was lower in PRE at 10-45 min (P ≤ 0.017), and in DUR at 30-60 min 218 
post-breakfast (P ≤ 0.041). Concentrations returned to baseline levels under all conditions thereafter 219 
(P > 0.05). Glycaemia across the post-breakfast period was significantly lower following whey 220 
preload compared with POST and CON conditions (AUC: PRE: 982 (SEM 30) vs POST: 1031 (SEM 221 
36) and CON: 1065 (SEM 37) mmol/l x 180 min; P ≤ 0.042), but not significantly different from the 222 
whey with meal condition (DUR: 1013 (SEM 32) mmol/l x 180 min; P = 0.77; Figure 2b). Glycaemia 223 
was not significantly different from CON when whey was supplemented during (P = 0.171) or after 224 
(P = 0.816) the breakfast meal. 225 
 226 
Postprandial plasma insulin concentrations displayed significant effects of time (P < 0.001) and 227 
significant condition x time interactions (P = 0.008; Figure 2c). At the time of breakfast consumption 228 
(0 min) insulin was elevated in PRE compared to CON (P = 0.04). Concentrations rose following 229 
breakfast consumption, remaining significantly elevated above baseline level at all time points 230 
between 15 and 120 min post-breakfast (P ≤ 0.007; Figure 2c). Insulin AUC across this period showed 231 
a reduced insulin response when whey was supplemented before breakfast compared with other 232 
supplementation times (AUC: PRE: 96340 (SEM 10807) vs DUR: 112344 (SEM 10310) and POST: 233 
121997 (SEM 15862) pmol/l x 180 min; P ≤ 0.032; Figure 2d), and was similar to the response 234 
following breakfast without additional protein (CON: 99115 (SEM 14656) pmol/l x 180 min; P > 0.05). 235 
When whey was supplemented after the meal, insulinaemia was ~23% greater than CON (P = 0.049). 236 
Insulin sensitivity did not significantly differ between conditions during the post-breakfast period 237 
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(Matsuda-ISI; PRE: 3.8 (SEM 0.6), DUR: 2.9 (SEM 0.5), POST: 2.8 (SEM 0.4), CON: 3.3 (SEM 0.5) 238 
arbitrary units; P = 0.161).  239 
 240 
Post-breakfast NEFA concentrations were significantly affected by time (P < 0.001) such that 241 
concentrations were immediately suppressed following breakfast consumption under all conditions, 242 
and remained significantly below baseline from 15-180 min post-breakfast (P ≤ 0.006; Figure 2e). 243 
There was no effect of condition (P = 0.611) and NEFA AUC was similar between conditions across 244 
this period (P = 0.517; Figure 2f).  245 
 246 
An effect of time (P < 0.001), but not condition (P = 0.26) or condition x time interaction (P = 0.423), 247 
was observed on appetite perceptions following breakfast. Combined appetite ratings were similarly 248 
suppressed under all conditions following breakfast consumption, reaching their nadir at 15-30 min 249 
post-consumption, the magnitude of which was not different between conditions (PRE: 14  (SEM  4), 250 
DUR: 15  (SEM  4), POST: 17  (SEM  4), CON: 20  (SEM  4) mm; P = 0.344; Figure 3a). Appetite 251 
subsequently increased gradually, reaching similar levels to baseline at 120-180 min post-breakfast 252 
in all conditions (P > 0.05). There were no significant differences in AUC between conditions for 253 
combined appetite score (Figure 3b) or individual subjective appetite components across this period 254 
(P > 0.05; Table 2).  255 
 256 
Post-lunch responses 257 
 258 
Following consumption of a standardised lunch meal, both glucose and insulin concentrations 259 
displayed a significant effect of time (P < 0.001), with no condition x time interactions observed 260 
(P > 0.05). Concentrations peaked similarly across all conditions before returning to pre-lunch levels 261 
at 60 and 90 min post-lunch for glucose and insulin respectively (Figure 4). Post-lunch AUC revealed 262 
no differences between conditions in glycaemia (P = 0.262) or insulinaemia (P = 0.271; Figure 4).  263 
 264 
Post-lunch NEFA concentrations were not influenced by condition (P = 0.346), with similar AUC 265 
observed between conditions (P = 0.587; Figure 4f). Concentrations were moderately suppressed at 266 
45-60 min post-lunch under all conditions, before returning to pre-lunch levels at 90-180 min (Figure 267 
4e). Appetite was similarly affected by consumption of lunch in all conditions (P = 0.423). An effect 268 
of time was present (P < 0.001), such that there was an immediate reduction in combined appetite 269 
score following lunch, before gradually returning to pre-lunch levels at 150-180 min post-270 
consumption across all conditions (Figure 3c). There were no significant differences observed in post-271 
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lunch AUC for combined appetite score (Figure 3d) or its constituent components of hunger, fullness, 272 
PFC and satisfaction between conditions (P > 0.05; Table 2). 273 
 274 
Plasma triglyceride 275 
 276 
Triglyceride concentrations increased similarly over the course of the experimental protocol in all 277 
conditions. Post hoc analysis of the main effect of time (P < 0.001) indicated that levels were elevated 278 
above baseline concentration from 60 min post-breakfast onwards (P ≤ 0.018), and continued to rise 279 
throughout (Figure 5a). There was no effect of condition on triglyceride concentrations (P = 0.653), 280 
and AUC was similar between conditions for triglyceride response across the full postprandial period 281 
(P = 0.64; Figure 5b).  282 
 283 
 284 
DISCUSSION 285 
 286 
The findings of the current study demonstrate that consumption of a 20 g whey protein bolus, either 287 
before or alongside a mixed-macronutrient breakfast, attenuates peak postprandial glucose excursions 288 
in centrally-obese, insulin resistant males. Furthermore, consuming whey as a preload appears to 289 
confer the greatest beneficial effect to reducing postprandial hyperglycaemia. Moreover, post-meal 290 
whey protein consumption raises insulinaemia but without a concomitant reduction of 291 
hyperglycaemia. The beneficial effects of prandial whey protein supplementation are acute, and do 292 
not carry forward to subsequent meals.   293 
 294 
Peak glucose excursions and glucose area under the curve were reduced when whey was 295 
supplemented as a preload or with the meal. Postprandial hyperglycaemia is a greater risk factor for 296 
CVD than increased fasting glucose in non-diabetics 3,4, where its contribution to overall glycaemia 297 
is particularly marked. Furthermore, postprandial glycaemic excursions have been established as the 298 
main causative factor in glycaemic variability in non-insulin treated individuals with impaired 299 
glucose tolerance 34, and such excursions manifest adverse metabolic effects via activation of 300 
oxidative stress and endothelial dysfunction 35. Thus, evidence supports recommending reductions in 301 
postprandial hyperglycaemia as a relevant clinical goal in delaying or preventing the onset of type 2 302 
diabetes 36. Our data show that a moderate 20 g dose of whey protein offers practical utility as a meal-303 
time aid for reducing the hyperglycaemic burden, with a post-breakfast reduction in peak glucose of 304 
17.0% and 9.2% when whey was consumed before or alongside the meal respectively. Additionally, 305 
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a 7.3% decrease in glucose AUC across the postprandial period was observed following the whey 306 
preload, devoid of any significant change in insulin AUC. Whilst it is understood that postprandial 307 
hyperglycaemia is predictive of various complications and metabolic derangements, as described 308 
above, the clinical significance of such a reduction in glucose AUC of the magnitude shown in our 309 
study, in terms of translation to a clinical end point, remains unclear.  310 
 311 
The mechanisms explaining the reduction in postprandial glycaemia are yet to be fully elucidated. 312 
Our data contrast with prior literature 19,21, in that the insulin concentrations were not elevated during 313 
the postprandial period with the preload supplementation strategy. However, at the onset of the 314 
breakfast ingestion, we observed raised insulin concentrations under PRE in comparison to CON 315 
(Figure 2). A reduction in the early postprandial insulin response to feeding is a characteristic 316 
associated with insulin resistance and type 2 diabetes 37, and thus the raised insulin may have 317 
contributed to clearing glucose, suppressing hepatic glucose output, and opposing the potential rise 318 
in glucagon that can occur with protein feeding. Furthermore, consuming whey as a preload is known 319 
to slow gastric emptying 19. Thus, a combined influence of raised insulin concentrations prior to meal 320 
ingestion and a slower rate of gastric emptying could explain the superior influence of the preload 321 
strategy on reducing postprandial glycaemia. This explanation is supported by insulin concentrations 322 
that were similar between DUR and CON, yet glycaemia was significantly lower with DUR. 323 
Moreover, insulin concentrations were elevated with post-meal supplementation, without any 324 
improvement in glycaemia.  325 
 326 
The effects of whey protein ingestion, independent of timing of consumption, were limited to glucose 327 
and insulin responses in the current study. Postprandial lipaemia was not affected by co-ingestion of 328 
whey protein with breakfast, which is in line with previous findings in normal-weight males 28 and 329 
those with and without type 2 diabetes 38, but differs from the findings of Pal et al. 39. Pal and 330 
colleagues observed a 21% reduction in plasma triglyceride AUC following 45 g whey, compared 331 
with the same dose of glucose, when administered alongside a mixed-macronutrient meal in obese 332 
females. Such a disparity cannot be attributed to differences in fat content of test meals, as 333 
postprandial triglyceride was unaffected when relatively low (the present study) and high 38 fat test 334 
meals have been supplemented with prior whey protein. The amount of supplemental whey 335 
administered by Pal et al. however, was over 2-fold greater than both these studies, which may have 336 
influenced the observed triglyceride-lowering effect.  337 
 338 
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Subjective appetite appeared to be unaffected by whey protein supplementation, regardless of 339 
condition. Prior research has demonstrated an appetite suppressing effect of whey protein, with wide 340 
ranging protocols and participants, e.g. in overweight males after a 55 g preload 40 and with a 15 g 341 
whey bolus in type 2 diabetes 16. In the study by King et al. pre-meal whey protein resulted in greater 342 
post-meal insulin concentrations compared to control, possibly playing a role in appetite 343 
suppressession 41,42. However, in the current study the elevated pre-meal insulin during PRE, and the 344 
greater insulin during POST, did not translate into changes in appetite sensations. A mixed effect of 345 
whey on subjective appetite ratings in non-diabetic individuals has previously been shown. Several 346 
studies have reported reductions in appetite 43-45, although the exact mechanisms remain to be 347 
elucidated, while others show no effect on perceptions of appetite with 46,47 or without reductions in 348 
energy intake 48. Future research should explore appetite sensations and energy intake following both 349 
acute and longer term use of prandial whey protein supplementation.   350 
 351 
Whey protein at breakfast did not affect post-lunch responses across all outcomes assessed in the 352 
present study. This appears to confirm previous findings in normal-weight individuals 28, and suggests 353 
that any effects of whey protein on postprandial glycaemia are transient, and may provide rationale 354 
for researchers to investigate the supplementation of whey protein at multiple sequential meals.  355 
 356 
To the authors’ knowledge, this was the first study to assess the effect of timing of whey protein 357 
consumption on post-meal glycaemia in a non-diabetic population. The methodology was 358 
strengthened by efforts to increase the ecological validity of findings, including administering a dose 359 
of protein that could realistically be supplemented alongside a meal, and timings of supplementation 360 
that would not inconvenience individuals wishing to carry out this strategy to reduce glycaemic 361 
excursions. Care was also taken to use foods that were typical of those consumed at breakfast and 362 
lunch meals across the population. Further examination of the findings, and associated mechanisms 363 
underpinning them, is however limited. The measurement of circulating concentrations of amino 364 
acids and incretin hormones, as well as rates of gastric emptying, may have been beneficial in this 365 
regard. Whilst the aim of the present study was to investigate the effect of whey protein 366 
supplementation and its timing, irrespective of the mechanisms of action, consideration should be 367 
given to incorporating these measures into future work.  368 
 369 
In summary, consumption of whey protein alongside a mixed-macronutrient meal attenuated 370 
postprandial glucose excursions in centrally-obese insulin resistant males. In addition, as 371 
hypothesised, consumption of whey as a preload had a similar effect on peak glucose, also attenuating 372 
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glycaemia over the subsequent 3 hours, with a simultaneously reduced insulin response. Reductions 373 
in postprandial glycaemia may be beneficial in preventing or delaying the progression from normal 374 
to impaired glucose tolerance or type 2 diabetes. Postprandial lipaemia and subjective appetite, 375 
contrary to the original hypothesis, were not affected by the supplementation of 20 g whey protein or 376 
its timing of consumption. The benefits of whey supplementation are acute and future research should 377 
explore glycaemic responses and macro and micronutrient intake following long-term 378 
supplementation.  379 
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FIGURES 547 
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 551 
 552 
Figure 1. Schematic representation of experimental trials. 553 
 554 
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 556 
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 559 
 560 
 561 
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 563 
Figure 2. Time course changes in glucose (a), insulin (c) and NEFA (e) concentrations and area under 564 
the curve for glucose (b), insulin (d) and NEFA (f) during the post-breakfast period (0-180 min). 565 
Significant differences (P < 0.05) between conditions at individual time points are defined as follows: 566 
20 
 
a, PRE vs CON; b, PRE vs POST; c, DUR vs CON; black dotted line indicates time of breakfast 567 
consumption; grey dotted lines indicate time of whey protein consumption during PRE and POST 568 
conditions. Bars sharing a common symbol differ significantly from one another (P < 0.05). Time 569 
course data were analysed using two-way (condition x time) repeated measures ANOVA. AUC data 570 
were analysed using one-way repeated measures ANOVA. Data are presented as mean with SEM. 571 
BL, baseline. 572 
 573 
 574 
 575 
Figure 3. Time course changes and area under the curve for combined appetite score during the post-576 
breakfast (a-b) and post-lunch (c-d) postprandial periods. Black dotted line indicates time of breakfast 577 
consumption; grey dotted lines indicate time of whey protein consumption during PRE and POST 578 
conditions. Time course data were analysed using two-way (condition x time) repeated measures 579 
21 
 
ANOVA. AUC data were analysed using one-way repeated measures ANOVA. Data are presented 580 
as mean with SEM. BL, baseline. 581 
 582 
 583 
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 584 
Figure 4. Time course changes in glucose (a), insulin (c) and NEFA (e) concentrations and area under 585 
the curve for glucose (b), insulin (d) and NEFA (f) during the post-lunch period (180-360 min). Time 586 
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course data were analysed using two-way (condition x time) repeated measures ANOVA. AUC data 587 
were analysed using one-way repeated measures ANOVA. Data are presented as mean with SEM.  588 
 589 
 590 
 591 
 592 
Figure 5. Time course changes (a) and area under the curve (b) for plasma triglyceride concentrations 593 
throughout the full experimental protocol (0-360 min). Black dotted line indicates time of breakfast 594 
consumption; grey dotted lines indicate time of whey protein consumption during PRE and POST 595 
conditions. Time course data were analysed using two-way (condition x time) repeated measures 596 
ANOVA. AUC data were analysed using one-way repeated measures ANOVA. Data are presented 597 
as mean with SEM. BL, baseline. 598 
 599 
 600 
 601 
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TABLES 609 
 610 
 611 
Table 1. Participant characteristics (mean values with standard errors, n = 13). 612 
 Mean SEM 
 
Characteristics    
Age (years) 39 3  
Body mass (kg) 117.9 3.7  
Stature (cm) 181.3 2.8  
BMI (kg/m2) 36.0 1.1  
Waist circumference (cm) 121.3 2.6  
Waist/hip ratio 1.00 0.01  
Waist/height ratio 0.67 0.02  
Fasting variables    
Blood glucose (mmol/l) 5.0 0.1  
Plasma insulin (pmol/l) 122.0 24.8  
HOMA-IR 6.4 1.2  
Plasma triglyceride (mmol/l) 1.91 0.17  
 613 
Fasting values are presented as mean of fasting samples for each main trial. 614 
 615 
 616 
Table 2. Area under the curve for components of subjective appetite during post-breakfast (0-180 minutes) and post-lunch (180-360 617 
minutes) postprandial periods (mean values with standard errors, n = 13). 618 
  Area under the curve 
  PRE 
 
DUR 
 
POST 
 
CON 
  Mean SEM 
 
Mean SEM 
 
Mean SEM 
 
Mean SEM 
             
Hunger 
(mm x 180 min) 
Post-breakfast 6033 801  6070 911  6461 887  7641 1095 
Post-lunch 6046 734  5651 954  6378 1012  6649 929 
             
Fullness 
(mm x 180 min) 
Post-breakfast 11350 885  11553 964  11107 965  9963 1139 
Post-lunch 11347 824  11980 974  11130 1080  11003 1007 
             
PFC 
(mm x 180 min) 
Post-breakfast 7303 1034  6642 1086  7448 1094  8761 1288 
Post-lunch 7499 1069  6882 1187  7423 1165  7707 1201 
             
Satisfaction 
(mm x 180 min) 
Post-breakfast 11203 929  11194 966  10767 969  10411 982 
Post-lunch 10941 881  11548 1018  11313 979  10767 980 
             
 619 
PFC, prospective food consumption. AUC data were analysed using one-way repeated measures ANOVA. 620 
 621 
 622 
